Pluristem Therapeutics Inc. is announcing that its subsidiary, Pluristem Ltd., has been awarded $3.3 million Israel Innovation Authority of the Israeli Ministry of Economy & Industry. The grant will support clinical trials as well as research and development activities for calendar year 2016.
Pluristem Awarded $3.3 Million!
1 min read Premium comments
Secondary
“We are delighted to receive the Israeli Innovation Authority Grant this year, ” stated Zami Aberman, chairman and CEO in the May 9, 2016 news release. “The continued backing of the Israeli Innovation Authority is a vote of confidence in Pluristem technology and strategy and support the execution of our plans.”
Karine Kleinhaus, M.D., M.P.H. is divisional vice president, North America for Pluristem. She told OTW, “Typically, it covers all of our activity (excluding G&A). We submit a grant request with the planned activities for the year, the Israel Innovation Authority of the Israeli Ministry of Economy & Industry makes an assessment of the grant request and approves the specific activities, which typically are in our entire field of operations: research, development, manufacturing, manufacturing scale up, quality, clinical trials, pre-clinical trials, regulation, etc.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.